The rise of copyright’s blockbuster initially fueled a period of growth for pharma, but recent shifts present a murky outlook for investors. Off-patent competitors are eroding earnings, and persistent patent https://sabrinadtiz528551.tokka-blog.com/41607107/sildenafil-and-pharma-a-volatile-play